Navigation Links
Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities
Date:12/1/2009

NEW YORK, Dec. 1 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Latin American Pharmaceutical Market Outlook To 2014: Policy environment, market analysis, forecasts and growth opportunities

http://www.reportlinker.com/p0165648/Latin-American-Pharmaceutical-Market-Outlook-To-2014-Policy-environment-market-analysis-forecasts-and-growth-opportunities.html

The $28.8bn Latin American market delivered 15.3% y-o-y growth in 2008 as per IMS Health data. The market is expected to grow to $51.3bn in 2014 at a CAGR of 10.1%. Inconsistency in regulatory protocol in the seven major Latin American countries - Brazil, Mexico, Venezuela, Argentina, Colombia, Chile and Peru - has been the greatest concern to research based pharmaceutical companies. Several companies faced severe sales erosion due to launch of unauthorized generic versions of their leading brands. However, situation has improved considerably ever since these countries became signatories to TRIPS and other international trade treaties. The improved regulatory environment is beckoning pharmaceutical companies of all types including research driven firms as well as generic players to Latin America. Companies that already have registered their presence in the region have raised investments in their local production facilities. They have also increased the number of clinical trials conducted in the region due to progress in regional healthcare standards and resources. Historically, multinational players have held a majority share of the Latin American market. However, the market share held by domestic companies have continued to grow, while that held by multinational companies is steadily declining. The volume based business model of domestic companies, focused on generics, has proven to be the growth formula for success in Latin America. Considering the domination of generics in the region, multinational drug firms have accelerated their entry into generic business by raising investments in their local production facilities as well as acquiring local players. The report details therapeutic segmentation of regional markets in light of subtle variations in strategies of major players across countries. Distribution of sales across therapeutic segments in the seven major Latin American countries have been analyzed, highlighting regional differences in brand dynamics, generic incursion suffered by major brands and recent drug launches. Further, the report examines the competitive landscape in the region as well as individual countries, analyzing the interplay of various drivers and resistors.

Table of Contents

Latin American Pharmaceutical Market Outlook to 2014

Executive Summary 12

Macroeconomics and health status 12

Pharmaceutical regulatory environment 13

Therapeutic market analysis 14

Competitive landscape 15

Scope and methodology 18

Scope 18

Key therapy areas covered in this report 18

Methodology 19

Chapter 1 Macroeconomics, demographics and health status 22

Summary 22

Introduction 23

Socioeconomic trends 23

Demographic trends 24

Health status 25

Disease burden in the Americas 26

Health expenditure 29

Chapter 2 Pharmaceutical regulatory environment 32

Summary 32

Introduction 33

Regulatory environment in Latin America 34

Intellectual property 35

Rising trial registrations 36

Regulatory harmonization and tie-ups 38

Compulsory licensing trends in Latin America 39

Generic drug policy 39

Prescription policies 41

Biosimilar regulatory pathway in Latin America 41

Regulatory systems in Latin America 42

Brazil 42

Intellectual property rights 42

Adverse event notification system 43

Drug advertising 43

Pricing 43

Mexico 43

Intellectual property rights 43

Adverse event notification 44

Drug advertising 44

Pricing 44

Venezuela 45

Intellectual property rights 46

Adverse event notification 46

Drug advertising 46

Pricing 46

Argentina 47

Intellectual property rights 47

Adverse event notification 47

Drug advertising 48

Pricing 48

Colombia 48

Intellectual property rights 48

Adverse event notification 48

Drug advertising 49

Pricing 49

Chile 49

Intellectual property rights 49

Adverse event notification 49

Drug advertising 50

Pricing 50

Intellectual property rights 50

Adverse event notification 50

Pricing 51

Chapter 3 Therapeutic market analysis 54

Summary 54

Introduction 55

Country wise sales distribution 55

Forecast country wise sales distribution 56

Key statistics 57

Leading drug classes 57

Leading brands in Latin America 58

Regional market analysis 58

Brazil 58

Key market statistics 58

Leading therapy segments 59

Leading brands 61

NME launches in 2008 62

DPP-IV inhibitors and incretin mimetics draw focus to diabetes management 63

Mexico 64

Key market statistics 64

Leading therapy segments 65

Leading brands 67

NME launches in 2008 67

Venezuela 68

Key market statistics 68

Leading therapy segments 69

Leading brands 70

NME launches in 2008 71

NMDA-receptor antagonists make entry 72

Argentina 72

Key market statistics 72

Leading therapy segments 73

Leading brands 74

NME launches in 2008 75

Diabetes management witnesses entry of DPP-IV inhibitors and

incretin mimetics 75

Colombia 76

Key market statistics 76

Leading therapy segments 77

Leading brands 78

NME launches in 2008 79

Bayer introduces PGI2 analogues for PAH therapy 79

Chile 80

Key market statistics 80

Leading therapy segments 81

Leading brands 82

NME launches in 2008 83

Januvia and Rasilez bring new treatment options in respective therapeutic areas 83

Key market statistics 84

Leading therapy segments 85

Leading brands 86

NME launches in 2008 86

Chapter 4 Competitive landscape 90

Summary 90

Introduction 91

Top 10 players in the Latin American pharmaceutical market in 2008 91

Forecast performance of the top 10 Latin American players 95

Market concentration/fragmentation analysis 96

Leading players in Latin America 97

Sanofi-Aventis 97

Regional sales 97

Therapeutic sales distribution 98

Leading brands 99

Pipeline 100

Competitive analysis 101

Novartis 102

Regional sales 103

Therapeutic sales distribution 104

Leading brands 105

Pipeline 106

Competitive analysis 106

Bayer 107

Regional sales 108

Therapeutic sales distribution 109

Leading brands 110

Pipeline 111

Competitive analysis 111

Pfizer 114

Regional sales 115

Therapeutic sales distribution 116

Leading brands 117

Pipeline 118

Competitive analysis 118

Schering-Plough 119

Regional sales 120

Therapeutic sales distribution 121

Leading brands 122

Pipeline 123

Competitive analysis 123

Competitive landscape across countries 125

Brazil 125

Mexico 128

Venezuela 130

Argentina 131

Colombia 132

Chile 133

Peru 136

Chapter 5 Appendix 140

Abbreviations 140

Index 142

List of Figures

Figure 1.1: Comparison of DALYs (000s) of American LMICs and global high-income countries, 2008 28

Figure 1.2: GDP and health expenditure trends, 2008 29

Figure 2.3: SWOT - Latin American regulatory landscape 34

Figure 2.4: Clinical trial registrations in Latin America, 2008 38

Figure 3.5: Forecast sizes of Latin American markets 57

Figure 4.6: Sales distribution of leading MNCs and local players by country, 2008 93

Figure 4.7: Regional sales distribution of top 20 MNCs, 2004-2008 94

Figure 4.8: Market concentration analysis, 2004-08 96

Figure 4.9: Yasmin/Yaz sales growth trend, 2004-08 112

Figure 4.10: Performance of erectile dysfunction products in Latin America, 2004-08 113

Figure 4.11: Changing competitive positions of top five dermatological product marketers, 2004-08 114

List of Tables

Table 1.1: Socioeconomic indicators of Latin American countries, 2008 23

Table 1.2: Demographic profile of Latin American countries, 2008 24

Table 1.3: Healthcare delivery parameters of major Latin American countries 26

Table 1.4: DALYs (000s) across LMICs in the Americas, 2008-2014 27

Table 1.5: Government-private healthcare expenditure pattern, 2006 30

Table 2.6: PhRMA Special 301 submission regarding Latin America, 2009 36

Table 2.7: Clinical trials in Latin America 37

Table 2.8: Prescription criteria and generic substitution laws in Latin America 41

Table 2.9: Developments in biosimilar regulatory pathway formulation in Latin America 42

Table 3.10: Country wise sales distribution in Latin America, 2008 55

Table 3.11: Country wise sales forecasts, 2008-14 56

Table 3.12: Leading drug classes in Latin America, 2008 57

Table 3.13: Leading brands in Latin America, 2008 58

Table 3.14: Leading therapy segments in Brazil, 2008 59

Table 3.15: Leading brands in Brazil, 2008 61

Table 3.16: NME launches in Brazil, 2008 62

Table 3.17: Newer drug classes in Brazil, 2007-08 63

Table 3.18: Leading therapy segments in Mexico, 2008 65

Table 3.19: Leading brands in Mexico, 2008 67

Table 3.20: NME launches in Mexico, 2008 67

Table 3.21: Leading therapy segments in Venezuela, 2008 69

Table 3.22: Leading brands in Venezuela, 2008 70

Table 3.23: NME launches in Venezuela, 2008 71

Table 3.24: Newer drug classes in Venezuela, 2007-08 72

Table 3.25: Leading therapy segments in Argentina, 2008 73

Table 3.26: Leading brands in Argentina, 2008 74

Table 3.27: NME launches in Argentina, 2008 75

Table 3.28: Newer drug classes in Argentina, 2007-08 75

Table 3.29: Leading therapy segments in Colombia, 2008 77

Table 3.30: Leading brands in Colombia, 2008 78

Table 3.31: NME launches in Colombia, 2008 79

Table 3.32: Newer drug classes in Colombia, 2007-08 79

Table 3.33: Leading therapy segments in Chile, 2008 81

Table 3.34: Leading brands in Chile, 2008 82

Table 3.35: NME launches in Chile, 2008 83

Table 3.36: Newer drug classes in Chile, 2007-08 83

Table 3.37: Leading therapy segments in Peru, 2008 85

Table 3.38: Leading brands in Peru, 2008 86

Table 3.39: NME launches in Peru, 2008 86

Table 4.40: Leading Latin American pharmaceutical companies, 2008 91

Table 4.41: Sales distribution between leading MNCs and domestic players, 2008 92

Table 4.42: Sales forecasts of top 10 Latin American players, 2009-14 95

Table 4.43: Regional sales distribution of Sanofi-Aventis, 2008 97

Table 4.44: Therapeutic sales distribution of Sanofi-Aventis, 2008 98

Table 4.45: Leading brands from Sanofi-Aventis, 2008 99

Table 4.46: Sanofi-Aventis' pipeline portfolio, September 2009 100

Table 4.47: Regional sales distribution of Novartis, 2008 103

Table 4.48: Therapeutic sales distribution of Novartis, 2008 104

Table 4.49: Leading brands from Novartis, 2008 105

Table 4.50: Novartis' pipeline portfolio, September 2009 106

Table 4.51: Regional sales distribution of Bayer, 2008 108

Table 4.52: Therapeutic sales distribution of Bayer, 2008 109

Table 4.53: Leading brands from Bayer, 2008 110

Table 4.54: Bayer's pipeline portfolio, September 2009 111

Table 4.55: Regional sales distribution of Pfizer, 2008 115

Table 4.56: Therapeutic sales distribution of Pfizer, 2008 116

Table 4.57: Leading brands from Pfizer, 2008 117

Table 4.58: Pfizer's pipeline portfolio, September 2009 118

Table 4.59: Regional sales distribution of Schering-Plough, 2008 120

Table 4.60: Therapeutic sales distribution of Schering-Plough, 2008 121

Table 4.61: Leading brands from Schering-Plough, 2008 122

Table 4.62: Schering-Plough's pipeline portfolio, September 2009 123

Table 4.63: Leading players in Brazil, 2008 125

Table 4.64: Leading players in Mexico, 2008 128

Table 4.65: Leading players in Venezuela, 2008 130

Table 4.66: Leading players in Argentina, 2008 131

Table 4.67: Leading players in Colombia, 2008 132

Table 4.68: Leading players in Chile, 2008 133

Table 4.69: Leading players in Peru, 2008 136

To order this report:

Pharmaceutical Industry: Latin American Pharmaceutical Market Outlook To 2014: Policy environment, market analysis, forecasts and growth opportunities

More Market Research Report



Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies
2. Reportlinker Adds The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
3. Reportlinker Adds Contract Research Outsourcing (CRO) - A Global Update of Market Trends & Opportunities
4. Reportlinker Adds Operating Tables - A World Market Review
5. Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report
6. Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015
7. Reportlinker Adds Outsourcing Opportunities in the Medical Device (2009 - 2014)
8. Reportlinker Adds Surgical Incision Closures - Global Trends
9. Reportlinker Adds Decubitus Ulcer Treatment Products - A Worldwide Market Review
10. Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective
11. Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
Breaking Medicine News(10 mins):